29.63USD+2.56%Mkt Cap: 1.43B USDP/E: —Last update: 2026-05-26
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse therm…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.43B USD
Enterprise Value1.51B USD
Revenue (TTM)140.49M USD
Gross Profit97.34M USD
Net Income (TTM)-153.49M USD
Revenue/Share2.879 USD
Last Price29.63 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees298
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)20.80
PEG—
EV/EBITDA-14.02
EV/Revenue10.77
P/S10.36
P/B-13.70
EPS (TTM)-2.74
EPS (Forward)1.44
52W Range
3.60590% of range32.37
52W High32.37 USD
52W Low3.605 USD
Profitability
Gross Margin88.66%
Oper. Margin-39.76%
EBITDA Margin-76.80%
Profit Margin-139.81%
ROE145.53%
ROA-76.57%
Growth
Revenue Growth151.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.44M USD
CapEx (TTM)289.00K USD
FCF Margin-77.78%
FCF Yield-7.62%
Net Debt56.82M USD
Net Debt/EBITDA-0.53
Balance Sheet
Debt/Equity-1.22
Current Ratio4.69
Quick Ratio3.87
Book Value/Sh-2.1810 USD
Cash/Share2.879 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)36.44 USD
Target Range18.00 USD – 45.00 USD
# Analysts9
Ownership
Shares Out.48.72M
Float43.18M
Insiders3.64%
Institutions99.44%
Short Interest
Short Ratio9.3d
Short % Float15.15%
Short % Out.14.85%
Shares Short7.24M
Short (prev mo.)8.35M
Technical
SMA 5022.68 (+30.6%)
SMA 20021.18 (+39.9%)
Beta1.59
S&P 52W Chg28.31%
Avg Vol (30d)905.54K
Avg Vol (10d)958.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—